SAB Biotherapeutics Statistics

Total Valuation

SABS has a market cap or net worth of $189.48 million. The enterprise value is $84.78 million.

Market Cap	189.48M
Enterprise Value	84.78M

Important Dates

The last earnings date was Thursday, November 13, 2025, after market close.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

SABS has 47.61 million shares outstanding. The number of shares has increased by 11.66% in one year.

Current Share Class	47.61M
Shares Outstanding	47.61M
Shares Change (YoY)	+11.66%
Shares Change (QoQ)	+737.29%
Owned by Insiders (%)	3.97%
Owned by Institutions (%)	10.98%
Float	22.59M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1,651.95
Forward PS	n/a
PB Ratio	1.15
P/TBV Ratio	1.15
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	739.18
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 10.50, with a Debt / Equity ratio of 0.04.

Current Ratio	10.50
Quick Ratio	10.32
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-174.11

Financial Efficiency

Return on equity (ROE) is 18.56% and return on invested capital (ROIC) is -25.38%.

Return on Equity (ROE)	18.56%
Return on Assets (ROA)	-22.76%
Return on Invested Capital (ROIC)	-25.38%
Return on Capital Employed (ROCE)	-25.02%
Revenue Per Employee	$1,821
Profits Per Employee	-$68,064
Employee Count	63
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +37.72% in the last 52 weeks. The beta is 0.59, so SABS's price volatility has been lower than the market average.

Beta (5Y)	0.59
52-Week Price Change	+37.72%
50-Day Moving Average	3.04
200-Day Moving Average	2.18
Relative Strength Index (RSI)	64.23
Average Volume (20 Days)	227,752

Short Selling Information

The latest short interest is 676,534, so 1.42% of the outstanding shares have been sold short.

Short Interest	676,534
Short Previous Month	696,993
Short % of Shares Out	1.42%
Short % of Float	2.99%
Short Ratio (days to cover)	2.77

Income Statement

In the last 12 months, SABS had revenue of $114,698 and -$4.29 million in losses. Loss per share was -$2.23.

Revenue	114,698
Gross Profit	-30.33M
Operating Income	-43.19M
Pretax Income	18.74M
Net Income	-4.29M
EBITDA	-40.09M
EBIT	-43.19M
Loss Per Share	-$2.23

Full Income Statement

Balance Sheet

The company has $110.88 million in cash and $6.19 million in debt, giving a net cash position of $104.69 million or $2.20 per share.

Cash & Cash Equivalents	110.88M
Total Debt	6.19M
Net Cash	104.69M
Net Cash Per Share	$2.20
Equity (Book Value)	165.07M
Book Value Per Share	3.48
Working Capital	102.48M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$37.53 million and capital expenditures -$55,377, giving a free cash flow of -$37.59 million.

Operating Cash Flow	-37.53M
Capital Expenditures	-55,377
Free Cash Flow	-37.59M
FCF Per Share	-$0.79

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-37,657.13%
Pretax Margin	16,338.32%
Profit Margin	16,338.32%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

SABS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.66%
Shareholder Yield	-11.66%
Earnings Yield	-2.26%
FCF Yield	-19.84%

Analyst Forecast

The average price target for SABS is $9.00, which is 126.13% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.00
Price Target Difference	126.13%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	142.28%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on January 5, 2024. It was a reverse split with a ratio of 1:10.

Last Split Date	Jan 5, 2024
Split Type	Reverse
Split Ratio	1:10

Scores

SABS has an Altman Z-Score of -0.07 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.07
Piotroski F-Score	1